Moss Adams Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

Moss Adams Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,172	Closed	-$1.04M	–	258
2025 Q2	$1.04M	Buy	24,172 +7,970	+49%	+$290K	0.09%	73
2025 Q1	$560K	Buy	16,202 +8,625	+114%	+$291K	0.06%	103
2024 Q4	$208K	Buy	+7,577	New	+$196K	0.02%	194

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moss Adams Wealth Advisors's BBIO Position: Q3 2025 in Review

Moss Adams Wealth Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 24,172 shares — an estimated $1.04M sold.

Moss Adams Wealth Advisors first reported a position in BBIO in Q4 2024 and held it in 3 quarters. The position peaked at $1.04M in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Moss Adams Wealth Advisors reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Moss Adams Wealth Advisors sold 24,172 BridgeBio Pharma shares in Q3 2025, an estimated $1.04M.
Moss Adams Wealth Advisors first reported a position in BridgeBio Pharma in Q4 2024 and held it in 3 quarters.
Moss Adams Wealth Advisors's BridgeBio Pharma position peaked at $1.04M in Q2 2025.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Moss Adams Wealth Advisors's 13F filing for Q3 2025, filed 21 Oct 2025.